J&J pro­pos­es slid­ing boost­er time­lines as FDA ques­tions lack of da­ta for Delta, old­er adults be­fore ad­comm

While both Pfiz­er/BioN­Tech and Mod­er­na are look­ing to ad­min­is­ter boost­ers for their Covid-19 vac­cines six months af­ter the ini­tial two-dose se­ries, J&J — which has vac­ci­nat­ed about 15 mil­lion Amer­i­cans so far with its one-shot vac­cine — is tak­ing a more unique ap­proach with boost­ers.

Ac­cord­ing to brief­ing doc­u­ments re­leased ahead of Fri­day’s FDA ad­comm on the boost­er dose, J&J is call­ing for its boost­ers to be ad­min­is­tered any­where from two months to six months fol­low­ing the ini­tial shot, de­pend­ing on the strength of the im­mune re­spons­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.